Hyperparathyroidism

• FDA label_change · 2022-10-20
  FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)

  FDA approved a supplemental application for ZEMPLAR (paricalcitol) filed by AbbVie, resulting in changes to its labeling.

• FDA label_change · 2020-12-04
  FDA Approved: CINACALCET — Supplemental Application (Cipla USA Inc.)

  The FDA approved a supplemental application for cinacalcet (Cipla USA Inc.), resulting in changes to CINACALCET's labeling.

• FDA label_change · 2019-10-17
  FDA Approved: PARICALCITOL — Supplemental Application (Accord Healthcare, Inc.)

  The FDA approved a supplemental application for paricalcitol from Accord Healthcare, resulting in a label change for this chronic kidney dis…

• FDA label_change · 2016-11-30
  FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)

  FDA approved a supplemental application for ZEMPLAR (paricalcitol) to update labeling and/or indications.

• FDA label_change · 2011-04-06
  FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)

  FDA approved a supplemental application for ZEMPLAR (paricalcitol) from AbbVie, updating its labeling.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA label_change · 2008-06-18
  FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)

  FDA overview of AbbVie’s supplemental application for ZEMPLAR (paricalcitol) to update labeling.

• FDA label_change · 2007-07-17
  FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)

  FDA approved a supplemental application for ZEMPLAR (paricalcitol) from AbbVie, resulting in changes to the product labeling. Paricalcitol i…